$Reviva Pharmaceuticals(RVPH.US)$Reviva Announces Alignment With FDA On Brilaroxazine Clinical Trials For NDA In Schizophrenia; FDA Accepts 4-Week RECOVER-2 Study
$SPDR標普生物科技ETF(XBI.US)$ The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023. As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
Analyst Mohit Bansal opines AbbVie might favour purchasing Cerevel due to its perceived clean IP and daily dosing for its principal schizophrenia medication. He anticipates potential benefit from peak adjustments in sales surpassing $3B.
$Reviva Pharmaceuticals(RVPH.US)$Press Release: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Dow Jones· 1 min ago
Reviva Pharmaceuticals股票討論區
$3.50 - $4?
don't mind if I do.
$Ambrx Biopharma(AMAM.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
Dow Jones· 1 min ago
暫無評論